188 related articles for article (PubMed ID: 22086161)
1. Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria.
Palma M; Hansson L; Choudhury A; Näsman-Glaser B; Eriksson I; Adamson L; Rossmann E; Widén K; Horváth R; Kokhaei P; Vertuani S; Mellstedt H; Osterborg A
Cancer Immunol Immunother; 2012 Jun; 61(6):865-79. PubMed ID: 22086161
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
Palma M; Hansson L; Mulder TA; Adamson L; Näsman-Glaser B; Eriksson I; Heimersson K; Ryblom H; Mozaffari F; Svensson A; Gentilcore G; Österborg A; Mellstedt H
Eur J Haematol; 2018 Jul; 101(1):68-77. PubMed ID: 29569742
[TBL] [Abstract][Full Text] [Related]
3. Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia.
Palma M; Adamson L; Hansson L; Kokhaei P; Rezvany R; Mellstedt H; Osterborg A; Choudhury A
Cancer Immunol Immunother; 2008 Nov; 57(11):1705-10. PubMed ID: 18663443
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL.
Kokhaei P; Rezvany MR; Virving L; Choudhury A; Rabbani H; Osterborg A; Mellstedt H
Leukemia; 2003 May; 17(5):894-9. PubMed ID: 12750703
[TBL] [Abstract][Full Text] [Related]
5. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL.
Kokhaei P; Choudhury A; Mahdian R; Lundin J; Moshfegh A; Osterborg A; Mellstedt H
Leukemia; 2004 Nov; 18(11):1810-5. PubMed ID: 15385926
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.
Hus I; Roliński J; Tabarkiewicz J; Wojas K; Bojarska-Junak A; Greiner J; Giannopoulos K; Dmoszyńska A; Schmitt M
Leukemia; 2005 Sep; 19(9):1621-7. PubMed ID: 15990861
[TBL] [Abstract][Full Text] [Related]
7. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
[TBL] [Abstract][Full Text] [Related]
8. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
9. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.
Alfaro C; Perez-Gracia JL; Suarez N; Rodriguez J; Fernandez de Sanmamed M; Sangro B; Martin-Algarra S; Calvo A; Redrado M; Agliano A; Gonzalez A; Rodriguez I; Bolaños E; Hervás-Stubbs S; Perez-Calvo J; Benito A; Peñuelas I; Vigil C; Richter J; Martinez-Forero I; Melero I
J Immunol; 2011 Dec; 187(11):6130-42. PubMed ID: 22048768
[TBL] [Abstract][Full Text] [Related]
10. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
11. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.
Giannopoulos K; Dmoszynska A; Kowal M; Rolinski J; Gostick E; Price DA; Greiner J; Rojewski M; Stilgenbauer S; Döhner H; Schmitt M
Leukemia; 2010 Apr; 24(4):798-805. PubMed ID: 20220777
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
[TBL] [Abstract][Full Text] [Related]
14. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
16. Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production.
Adamson L; Palma M; Choudhury A; Eriksson I; Näsman-Glaser B; Hansson M; Hansson L; Kokhaei P; Osterborg A; Mellstedt H
Scand J Immunol; 2009 Jun; 69(6):529-36. PubMed ID: 19439014
[TBL] [Abstract][Full Text] [Related]
17. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides.
Scheibenbogen C; Schadendorf D; Bechrakis NE; Nagorsen D; Hofmann U; Servetopoulou F; Letsch A; Philipp A; Foerster MH; Schmittel A; Thiel E; Keilholz U
Int J Cancer; 2003 Mar; 104(2):188-94. PubMed ID: 12569574
[TBL] [Abstract][Full Text] [Related]
18. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression.
von Euw EM; Barrio MM; Furman D; Levy EM; Bianchini M; Peguillet I; Lantz O; Vellice A; Kohan A; Chacón M; Yee C; Wainstok R; Mordoh J
J Transl Med; 2008 Jan; 6():6. PubMed ID: 18221542
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]